Aleksandar Ivovic1, Andrei I Oprescu2, Khajag Koulajian1, Yusaku Mori3, Judith A Eversley1, Liling Zhang4, Rodolfo Nino-Fong5, Gary F Lewis1,6,7, Marc Y Donath8, Michael Karin9, Michael B Wheeler1, Jan Ehses10,11, Allen Volchuk12, Catherine B Chan13,14, Adria Giacca15,16,17,18. 1. Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, M5S 1A8. 2. Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 3. Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Shinagawa, Tokyo, Japan. 4. Division of Cellular and Molecular Biology, Toronto General Research Institute, University Health Network, Toronto, ON, Canada. 5. Department of Biomedical Sciences, Ross University School of Veterinary Medicine, Basseterre, St Kitts and Nevis. 6. Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 7. Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada. 8. Department of Endocrinology, Diabetes, and Metabolism, University Hospital Basel, Basel, Switzerland. 9. Department of Pharmacology, University of California, San Diego, School of Medicine, La Jolla, CA, USA. 10. Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 11. Child and Family Research Institute, Vancouver, BC, Canada. 12. Keenan Research Centre for Biomedical Science, St Michael's Hospital, Toronto, ON, Canada. 13. Department of Agriculture, Food and Nutritional Sciences, Faculty of Agricultural, Life and Environmental Sciences, University of Alberta, Edmonton, AB, Canada. 14. Department of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. 15. Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, M5S 1A8. adria.giacca@utoronto.ca. 16. Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. adria.giacca@utoronto.ca. 17. Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. adria.giacca@utoronto.ca. 18. Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada. adria.giacca@utoronto.ca.
Abstract
AIMS/HYPOTHESIS: We have previously shown that oxidative stress plays a causal role in beta cell dysfunction induced by fat. Here, we address whether the proinflammatory kinase inhibitor of (nuclear factor) κB kinase β (IKKβ), which is activated by oxidative stress, is also implicated. METHODS: Fat (oleate or olive oil) was infused intravenously in Wistar rats for 48 h with or without the IKKβ inhibitor salicylate. Thereafter, beta cell function was evaluated in vivo using hyperglycaemic clamps or ex vivo in islets isolated from fat-treated rats. We also exposed rat islets to oleate in culture, with or without salicylate and 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline; BMS-345541 (BMS, another inhibitor of IKKβ) and evaluated beta cell function in vitro. Furthermore, oleate was infused in mice treated with BMS and in beta cell-specific Ikkb-null mice. RESULTS: 48 h infusion of fat impaired beta-cell function in vivo, assessed using the disposition index (DI), in rats (saline: 1.41 ± 0.13; oleate: 0.95 ± 0.11; olive oil [OLO]: 0.87 ± 0.15; p < 0.01 for both fats vs saline) and in mice (saline: 2.51 ± 0.39; oleate: 1.20 ± 0.19; p < 0.01 vs saline) and ex vivo (i.e., insulin secretion, units are pmol insulin islet-1 h-1) in rat islets (saline: 1.51 ± 0.13; oleate: 1.03 ± 0.10; OLO: 0.91 ± 0.13; p < 0.001 for both fats vs saline) and the dysfunction was prevented by co-infusion of salicylate in rats (oleate + salicylate: 1.30 ± 0.09; OLO + salicylate: 1.33 ± 0.23) or BMS in mice (oleate + BMS: 2.25 ± 0.42) in vivo and by salicylate in rat islets ex vivo (oleate + salicylate: 1.74 ± 0.31; OLO + salicylate: 1.54 ± 0.29). In cultured islets, 48 h exposure to oleate impaired beta-cell function ([in pmol insulin islet-1 h-1] control: 0.66 ± 0.12; oleate: 0.23 ± 0.03; p < 0.01 vs saline), an effect prevented by both inhibitors (oleate + salicylate: 0.98 ± 0.08; oleate + BMS: 0.50 ± 0.02). Genetic inhibition of IKKβ also prevented fat-induced beta-cell dysfunction ex vivo ([in pmol insulin islet-1 h-1] control saline: 0.16 ± 0.02; control oleate: 0.10 ± 0.02; knockout oleate: 0.17 ± 0.04; p < 0.05 control saline vs. control oleate) and in vivo (DI: control saline: 3.86 ± 0.40; control oleate: 1.95 ± 0.29; knockout oleate: 2.96 ± 0.24; p < 0.01 control saline vs control oleate). CONCLUSIONS/ INTERPRETATION: Our results demonstrate a causal role for IKKβ in fat-induced beta cell dysfunction in vitro, ex vivo and in vivo.
AIMS/HYPOTHESIS: We have previously shown that oxidative stress plays a causal role in beta cell dysfunction induced by fat. Here, we address whether the proinflammatory kinase inhibitor of (nuclear factor) κB kinase β (IKKβ), which is activated by oxidative stress, is also implicated. METHODS: Fat (oleate or olive oil) was infused intravenously in Wistar rats for 48 h with or without the IKKβ inhibitor salicylate. Thereafter, beta cell function was evaluated in vivo using hyperglycaemic clamps or ex vivo in islets isolated from fat-treated rats. We also exposed rat islets to oleate in culture, with or without salicylate and 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline; BMS-345541 (BMS, another inhibitor of IKKβ) and evaluated beta cell function in vitro. Furthermore, oleate was infused in mice treated with BMS and in beta cell-specific Ikkb-null mice. RESULTS: 48 h infusion of fat impaired beta-cell function in vivo, assessed using the disposition index (DI), in rats (saline: 1.41 ± 0.13; oleate: 0.95 ± 0.11; olive oil [OLO]: 0.87 ± 0.15; p < 0.01 for both fats vs saline) and in mice (saline: 2.51 ± 0.39; oleate: 1.20 ± 0.19; p < 0.01 vs saline) and ex vivo (i.e., insulin secretion, units are pmol insulin islet-1 h-1) in rat islets (saline: 1.51 ± 0.13; oleate: 1.03 ± 0.10; OLO: 0.91 ± 0.13; p < 0.001 for both fats vs saline) and the dysfunction was prevented by co-infusion of salicylate in rats (oleate + salicylate: 1.30 ± 0.09; OLO + salicylate: 1.33 ± 0.23) or BMS in mice (oleate + BMS: 2.25 ± 0.42) in vivo and by salicylate in rat islets ex vivo (oleate + salicylate: 1.74 ± 0.31; OLO + salicylate: 1.54 ± 0.29). In cultured islets, 48 h exposure to oleate impaired beta-cell function ([in pmol insulin islet-1 h-1] control: 0.66 ± 0.12; oleate: 0.23 ± 0.03; p < 0.01 vs saline), an effect prevented by both inhibitors (oleate + salicylate: 0.98 ± 0.08; oleate + BMS: 0.50 ± 0.02). Genetic inhibition of IKKβ also prevented fat-induced beta-cell dysfunction ex vivo ([in pmol insulin islet-1 h-1] control saline: 0.16 ± 0.02; control oleate: 0.10 ± 0.02; knockout oleate: 0.17 ± 0.04; p < 0.05 control saline vs. control oleate) and in vivo (DI: control saline: 3.86 ± 0.40; control oleate: 1.95 ± 0.29; knockout oleate: 2.96 ± 0.24; p < 0.01 control saline vs control oleate). CONCLUSIONS/ INTERPRETATION: Our results demonstrate a causal role for IKKβ in fat-induced beta cell dysfunction in vitro, ex vivo and in vivo.
Authors: James R Burke; Mark A Pattoli; Kurt R Gregor; Patrick J Brassil; John F MacMaster; Kim W McIntyre; Xiaoxia Yang; Violetta S Iotzova; Wendy Clarke; Joann Strnad; Yuping Qiu; F Christopher Zusi Journal: J Biol Chem Date: 2002-10-25 Impact factor: 5.157
Authors: Sunshin Kim; Isabelle Millet; Hun Sik Kim; Ja Young Kim; Myoung Sook Han; Moon-Kyu Lee; Kwang-Won Kim; Robert S Sherwin; Michael Karin; Myung-Shik Lee Journal: Proc Natl Acad Sci U S A Date: 2007-01-31 Impact factor: 11.205
Authors: Tejas Desai; Khajag Koulajian; Aleksandar Ivovic; Danna M Breen; Lemieux Luu; Evangelia L Tsiani; Michael B Wheeler; Adria Giacca Journal: Nutr Diabetes Date: 2019-03-19 Impact factor: 5.097
Authors: Justin Hou Ming Yung; Lucy Shu Nga Yeung; Aleksandar Ivovic; Yao Fang Tan; Emelien Mariella Jentz; Battsetseg Batchuluun; Himaben Gohil; Michael B Wheeler; Jamie W Joseph; Adria Giacca; Mortimer Mamelak Journal: Cells Date: 2022-02-04 Impact factor: 6.600
Authors: Samuel Treviño; Alfonso Díaz; Eduardo Sánchez-Lara; Brenda L Sanchez-Gaytan; Jose Manuel Perez-Aguilar; Enrique González-Vergara Journal: Biol Trace Elem Res Date: 2018-10-22 Impact factor: 3.738